Business
Novo Nordisk Reports Promising Trial Results for Next-Gen Obesity Drug, Shares Surge
Novo Nordisk, Europe’s largest pharmaceutical company, announced encouraging trial results for its next-generation obesity drug, amycretin, propelling its shares to a 7.13% gain in Copenhagen on Friday.
Key Trial Findings
The trial revealed that patients on the highest dose of 20 milligrams of amycretin achieved an estimated weight loss of 22% over 36 weeks. This result closely rivals Eli Lilly’s obesity drug Zepbound, which achieved a 22.5% weight loss over 72 weeks, and Lilly’s next-generation treatment, retatrutide, which reported a 24.4% weight reduction over 48 weeks.
Novo Nordisk’s amycretin is seen as a major contender in the competitive weight-loss drug market, particularly as the patent for its blockbuster treatment Wegovy is set to expire in the early 2030s.
Advancements in Treatment
Amycretin represents a significant step forward in weight-loss therapies, combining the effects of two hormones, glucagon-like peptide-1 (GLP-1) and amylin. This dual action enhances satiety and regulates blood sugar levels, providing a more comprehensive approach compared to Wegovy, which focuses solely on GLP-1.
The trials tested once-weekly injections of amycretin in 125 participants, showing:
- 9.7% weight loss with a 1.25-milligram dose over 20 weeks.
- 16.2% weight loss with 5 milligrams over 28 weeks.
- 22.1% weight loss with 20 milligrams over 36 weeks.
Most side effects were gastrointestinal and mild to moderate in severity. Novo Nordisk plans to advance amycretin into further clinical trials for adults with obesity or overweight conditions.
Market Impact and Competition
Following the announcement, Novo Nordisk’s shares saw a significant surge, recovering from a 14% decline over the past year. Meanwhile, Eli Lilly, a key competitor, experienced a brief 1.2% dip in U.S. markets before closing 2.45% higher.
Eli Lilly is also making strides with its oral weight-loss pill, orforglipron, which demonstrated a 14.7% weight loss over 36 weeks in a mid-stage trial. Oral treatments are gaining traction due to their convenience and cost-effectiveness compared to injectable therapies.
Novo Nordisk is developing an oral version of amycretin, showing a 13.1% weight reduction in trials, although this formulation presented more side effects. Its oral semaglutide trials reported a 15% weight loss over 68 weeks.
Outlook
With amycretin’s promising results and Wegovy’s robust sales, which rose 79% year-on-year in Q3, Novo Nordisk is poised for growth in the weight-loss drug market. The company’s fourth-quarter and full-year earnings are set to be released on February 5, offering further insights into its performance amid intensifying competition.
Business
Global Markets Rise as US–Iran Talks Ease Sentiment, but Oil and Geopolitical Risks Persist
Global financial markets advanced on Friday as investors reacted cautiously to signs of progress in US–Iran negotiations, though ongoing disruption to shipping through the Strait of Hormuz and elevated oil prices kept risk sentiment fragile.
European equities opened higher across the board. The DAX gained 0.64%, supported by a 3.61% rise in Deutsche Post AG shares. France’s CAC 40 climbed 0.65%, led by a 3.43% jump in STMicroelectronics. In London, the FTSE 100 rose 0.38%, with gains in financial stocks including 3i Group, while the Euro Stoxx 50 added 0.88%.
Currency markets were relatively steady, with the euro trading at $1.161 and the British pound at $1.342 in early European trading. Sentiment was also lifted by better-than-expected economic data from Germany, where first-quarter growth came in at 0.4% year on year and consumer confidence improved heading into June, offering cautious optimism for Europe’s largest economy.
Asian markets followed the upward trend. Japan’s Nikkei 225 surged 2.7% to 63,339 after data showed inflation easing to a four-year low of 1.4% in April. Taiwan’s Taiex rose 2.2%, while Hong Kong’s Hang Seng and China’s Shanghai Composite each gained 0.9%. South Korea, Australia, and India also posted modest increases, reflecting broad regional strength.
Wall Street had earlier closed slightly higher. The S&P 500 added 0.2%, the Dow Jones rose 0.6%, and the Nasdaq edged up 0.1%. However, technology stocks showed mixed signals, with Nvidia falling 1.8% despite strong quarterly results, as investors weighed valuations against broader market uncertainty.
Oil markets remained the key source of volatility. Brent crude climbed 2.3% to $104.97 a barrel, while US West Texas Intermediate rose 1.8% to $98.10. Prices remain significantly above pre-conflict levels, driven by continued disruption in the Strait of Hormuz, through which roughly a quarter of global seaborne oil flows pass.
Shipping through the strategic waterway remains constrained, with limited signs of recovery as diplomatic negotiations continue without resolution. Analysts say markets are highly sensitive to developments in talks between Washington and Tehran, with ING commodities strategists noting that optimism exists but uncertainty dominates trading conditions.
Geopolitical tensions also weighed on policy discussions in Washington, where a planned congressional vote on war powers legislation was postponed amid insufficient support.
In bond markets, US Treasury yields eased slightly to 4.57% after earlier spikes driven by inflation concerns linked to energy prices. The movement reflected ongoing caution among investors balancing growth expectations with persistent geopolitical risk.
Corporate earnings added a bright spot in Asia, where Lenovo Group surged more than 20% after reporting stronger-than-expected quarterly revenue of $21.6 billion, driven by robust performance in its PC and smart devices division.
Business
Goldman Sachs tapped to lead SpaceX IPO as Musk eyes record-breaking market debut
Business
Greek Stocks Stage Remarkable Comeback After Years of Financial Turmoil
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
